|
|
|
|
Drug development |
Research Strategy |
| The aim of the AnaMar research program is to discover and develop new disease-modifying anti-rheumatic drugs (DMARDS) that ideally (i) suppress local joint inflammation, inflammatory pain, and cartilage destruction, (ii) target novel cellular pathways, and (iii) are small molecules. |
AnaMar's unique platform |
AnaMar and its partners have a unique platform of expertise and technology enabling cutting-edge research in the identification of new compounds, mechanisms and interactions in joint cartilage.
|
Models of chronic joint disease |
Pharmacological screening of AnaMar's drug candidates are perfomed in vitro, in which the production of pro-inflammatory mediators can be measured in cultures of fibroblast-like synoviocytes, macrophages and chondrocytes. We also use cartilage explants to screen for cartilage protective effects of our drug compounds. After successful in vitro profiling, pharmacological activity is established in disease models. |
|
|
AnaMar's Drug Projects |
|
|
| Therapeutic area: |
| Inflammation, Immunomodulation |
| Inflammation, Immunomodulation |
| Inflammation, Immunomodulation |
| Wound healing, Topical treatment |
| Inflammation, Neuroprotection |
|
|
|
|
|
|
|
|
